当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Older women's experience with breast cancer treatment decisions.

Older women's experience with breast cancer treatment decisions.

Abstract：

:The purpose of this study was to better understand older women's experience with breast cancer treatment decisions. We conducted a longitudinal study of non-demented, English-speaking women ≥ 65 years recruited from three Boston-based breast imaging centers. We interviewed women at the time of breast biopsy (before they knew their results) and 6 months later. At baseline, we assessed intention to accept different breast cancer treatments, sociodemographic, and health characteristics. At follow-up, we asked women about their involvement in treatment decisions, to describe how they chose a treatment, and influencing factors. We assessed tumor characteristics through chart abstraction. We used quantitative and qualitative analyses. Seventy women (43 ≥ 75 years) completed both interviews and were diagnosed with breast cancer; 91 % were non-Hispanic white. At baseline, women 75+ were less likely than women 65-74 to report that they would accept surgery and/or take a medication for ≥ 5 years if recommended for breast disease. Women 75+ were ultimately less likely to receive hormonal therapy for estrogen receptor positive tumors than women 65-74. Women 75+ asked their surgeons fewer questions about their treatment options and were less likely to seek information from other sources. A surgeon's recommendation was the most influential factor affecting older women's treatment decisions. In open-ended comments, 17 women reported having no perceived choice about treatment and 42 stated they simply followed their physician's recommendation for at least one treatment choice. In conclusion, to improve care of older women with breast cancer, interventions are needed to increase their engagement in treatment decision-making.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Schonberg MA,Birdwell RL,Bychkovsky BL,Hintz L,Fein-Zachary V,Wertheimer MD,Silliman RA

doi

10.1007/s10549-014-2921-y

subject

Has Abstract

pub_date

2014-05-01 00:00:00

pages

211-23

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

145

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Involvement of early growth response factors in TNFα-induced aromatase expression in breast adipose.

    abstract：:Expression of the oestrogen producing enzyme, aromatase, is regulated in a tissue-specific manner by its encoding gene CYP19A1. In post-menopausal women, the major site for oestrogen production in the breast is the adipose, where CYP19A1 transcription is driven by the distal promoter I.4 (PI.4). Transcripts via this p...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2413-5

    authors： To SQ,Simpson ER,Knower KC,Clyne CD

    更新日期：2013-02-01 00:00:00

  • Dietary fiber is associated with serum sex hormones and insulin-related peptides in postmenopausal breast cancer survivors.

    abstract：OBJECTIVE:To measure the association between dietary fiber intake and eleven hormones and peptides in postmenopausal breast cancer survivors. METHODS:Intake of fiber from food and supplements was measured two to three years after breast cancer diagnosis in 493 postmenopausal women from three western states. Concurrent...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9834-y

    authors： Wayne SJ,Neuhouser ML,Ulrich CM,Koprowski C,Baumgartner KB,Baumgartner RN,McTiernan A,Bernstein L,Ballard-Barbash R

    更新日期：2008-11-01 00:00:00

  • Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.

    abstract：:The AZURE trial is an ongoing phase III, academic, multi-centre, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women with stage II/III breast cancer. Here, we report the safety and tolerability profile of ZOL in this setting. Eligible patients received (neo)adjuvant...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-011-1429-y

    authors： Coleman R,Woodward E,Brown J,Cameron D,Bell R,Dodwell D,Keane M,Gil M,Davies C,Burkinshaw R,Houston SJ,Grieve RJ,Barrett-Lee PJ,Thorpe H

    更新日期：2011-06-01 00:00:00

  • Patient-reported outcome after oncoplastic breast surgery compared with conventional breast-conserving surgery in breast cancer.

    abstract：INTRODUCTION:Oncoplastic breast surgery (OBS) has developed as an extension of breast-conserving surgery (BCS) in an effort to improve esthetic and functional outcome following surgery for breast cancer. The aim of the present study was to evaluate the possible benefits of OBS, as compared with BCS, with regard to heal...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05544-2

    authors： Rose M,Svensson H,Handler J,Hoyer U,Ringberg A,Manjer J

    更新日期：2020-02-01 00:00:00

  • Phosphocitrate inhibits calcium hydroxyapatite induced mitogenesis and upregulation of matrix metalloproteinase-1, interleukin-1beta and cyclooxygenase-2 mRNA in human breast cancer cell lines.

    abstract：:Microcalcifications containing calcium hydroxyapatite (HA) are often associated with malignant human breast lesions. Frequently, they are the only mammographic features that indicate the presence of a tumoural lesion. We previously reported the induction of both mitogenesis and prostaglandin E2 (PGE2) production and t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1023908307108

    authors： Cooke MM,McCarthy GM,Sallis JD,Morgan MP

    更新日期：2003-05-01 00:00:00

  • Pathology of borderline HER-2/neu breast carcinoma: a biologically distinct phenotype.

    abstract：PURPOSE:The significance of HER-2/neu results obtained by immunohistochemical analyses (IHC) which are neither negative nor strongly positive is controversial. The incidence of fluorescence in situ hybridization (FISH) positivity in these tumors is small and the implication is that these borderline results represent la...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-005-9136-1

    authors： Killeen JL,Ortega-Lopez A,Shaha J,Shaha SH,Fu JB

    更新日期：2006-07-01 00:00:00

  • Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study.

    abstract：:Five-year breast cancer survivors, diagnosed after 65 years of age, may develop more incident comorbidities than similar populations free of cancer. We investigated whether older breast cancer survivors have a similar comorbidity burden 6-15 years after cancer diagnosis to matched women free of breast cancer at start ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-3021-8

    authors： Jordan JH,Thwin SS,Lash TL,Buist DS,Field TS,Haque R,Pawloski PA,Petersen HV,Prout MN,Quinn VP,Yood MU,Silliman RA,Geiger AM

    更新日期：2014-07-01 00:00:00

  • Revealing clonality and subclonality of driver genes for clinical survival benefits in breast cancer.

    abstract：PURPOSE:Genomic studies have revealed that genomic aberrations play important roles in the progression of this disease. The aim of this study was to evaluate the associations between clinical survival outcomes of the clonality and subclonality status of driver genes in breast cancer. METHODS:We performed an integrated...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05153-8

    authors： Lan Y,Zhao E,Luo S,Xiao Y,Li X,Cheng S

    更新日期：2019-05-01 00:00:00

  • Fertility preservation does not delay the initiation of chemotherapy in breast cancer patients treated with adjuvant or neo-adjuvant chemotherapy.

    abstract：PURPOSE:To investigate whether fertility preservation (FP) in adult women diagnosed with breast cancer (BC) may impact the time interval between diagnosis and start of chemotherapy in an adjuvant or neo-adjuvant setting. METHODS:Retrospective cohort study of breast cancer patients diagnosed between January 2012 and De...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05858-1

    authors： D'Hondt C,Vanhoeij M,Van Moer E,Segers I,Fontaine C,Tournaye H,De Vos M

    更新日期：2020-11-01 00:00:00

  • Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene.

    abstract：:Tamoxifen has been used for the treatment of breast cancer since the 1970s, but is considered a carcinogen because it has been linked to liver cancer in rats and an increased risk of endometrial cancer in patients. In rats, DNA adducts appear to be responsible for carcinogenesis, but their contribution to carcinogenes...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006311214152

    authors： Hellmann-Blumberg U,Taras TL,Wurz GT,DeGregorio MW

    更新日期：2000-03-01 00:00:00

  • Long-term risk of medical conditions associated with breast cancer treatment.

    abstract：:Early and late effects of cancer treatment are of increasing concern with growing survivor populations, but relevant data are sparse. We sought to determine the prevalence and hazard ratio of such effects in breast cancer cases. Women with invasive breast cancer and women with no cancer history recruited for a cancer ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-2928-4

    authors： Hill DA,Horick NK,Isaacs C,Domchek SM,Tomlinson GE,Lowery JT,Kinney AY,Berg JS,Edwards KL,Moorman PG,Plon SE,Strong LC,Ziogas A,Griffin CA,Kasten CH,Finkelstein DM

    更新日期：2014-05-01 00:00:00

  • A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer.

    abstract：PURPOSE:This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer. PATIENTS AND METHODS:The study enrolled 155 women with pathologically confirmed and measurable metastatic adenocarcinoma of t...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1023/a:1021384318470

    authors： Loesch DM,Asmar L,Canfield VA,Parker GA,Hynes HE,Ellis PG,Ferri WA Jr,Robert NJ

    更新日期：2003-01-01 00:00:00

  • Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors.

    abstract：:Identification of novel targets for the treatment of basal-like breast cancer is essential for improved outcomes in patients with this disease. This study investigates the association of MMP7 expression and MMP7 promoter methylation with subtype and outcome in breast cancer patient cohorts. Immunohistochemical analysi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-2989-4

    authors： Sizemore ST,Sizemore GM,Booth CN,Thompson CL,Silverman P,Bebek G,Abdul-Karim FW,Avril S,Keri RA

    更新日期：2014-07-01 00:00:00

  • Identification of a novel mutations BRCA1*c.80 + 3del4 and BRCA2*c.6589delA in Slovak HBOC families.

    abstract：:Mutations in the BRCA1 and BRCA2 genes account for the majority of hereditary breast ovarian cancer (HBOC) cases. However, after BRCA1 and BRCA2 screening still the most HBOC cases remain negative for any mutational event. Accordingly, in these cases raises the relevance to analyze the unusual BRCA1/2 variants of unce...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0244-6

    authors： Konecny M,Vizvaryova M,Zavodna K,Behulova R,Gerykova Bujalkova M,Krivulcik T,Cisarik F,Kausitz J,Weismanova E

    更新日期：2010-01-01 00:00:00

  • Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?

    abstract：:Clinical evidence regarding the value of MRI for therapy responses assessment in breast cancer is increasing. The objective of this study is to compare the diagnostic capability of diffusion-weighted MR imaging (DW-MRI) and contrast-enhanced MR imaging (CE-MRI) to evaluate and predict pathological response in breast c...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10549-012-2033-5

    authors： Wu LM,Hu JN,Gu HY,Hua J,Chen J,Xu JR

    更新日期：2012-08-01 00:00:00

  • A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels.

    abstract：:In contrast to deoxyribose or arabinose containing nucleoside analogs that are currently established for cancer therapeutics, 8-chloro-adenosine (8-Cl-Ado) possesses a ribose sugar. This unique nucleoside analog is RNA-directed and is in a phase I clinical trial for hematological malignancies. RNA-directed therapies a...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0481-3

    authors： Stellrecht CM,Ayres M,Arya R,Gandhi V

    更新日期：2010-06-01 00:00:00

  • Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure.

    abstract：:It is still controversial whether the identification of micrometastases and isolated tumor cells in the axillary lymph nodes of patients with breast cancer has any prognostic value. We evaluated the prognostic role of isolated tumor cells and micrometastases in the axillary lymph nodes in 3,158 consecutive patients pT...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0446-6

    authors： Montagna E,Viale G,Rotmensz N,Maisonneuve P,Galimberti V,Luini A,Intra M,Veronesi P,Mazzarol G,Pruneri G,Renne G,Torrisi R,Cardillo A,Cancello G,Goldhirsch A,Colleoni M

    更新日期：2009-11-01 00:00:00

  • Hormones and hormone receptors in the etiology of breast cancer.

    abstract：:Many epidemiologic features of breast cancer suggest that endogenous hormones are of importance in the genesis of this disease. Endocrinologic studies based on total levels of various hormones in serum and urine have provided etiologic clues, but have failed to yield a clear understanding of the hormonal aberrations t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：

    authors： Thomas DB

    更新日期：1986-01-01 00:00:00

  • The influence of clinical information on the accuracy of diagnostic mammography.

    abstract：OBJECTIVE:This study examined the influence of knowledge of clinical information on the accuracy of mammography in women referred for investigation of breast symptoms. METHODS:Subjects were sampled from all women consecutively attending a symptomatic breast clinic and aged 25-55 years. This included all 240 women show...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/B:BREA.0000025416.66632.84

    authors： Houssami N,Irwig L,Simpson JM,McKessar M,Blome S,Noakes J

    更新日期：2004-06-01 00:00:00

  • Adjuvant systemic therapy: state of the art, 1989.

    abstract：:After more than 100 reported randomized trials of systemic adjuvant therapy in breast cancer, it is clear that this therapy will prolong the time to recurrence and the survival time significantly, at least in some patient subsets. But there is less than complete agreement as to which subsets, which therapies, how much...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验,评审

    doi：10.1007/BF01805971

    authors： Henderson IC

    更新日期：1989-10-01 00:00:00

  • Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

    abstract：:Erratum to: Breast Cancer Res Treat (2013),138:369–381,DOI 10.1007/s10549-012-2389-6. In the original publication of the article, the Fig. 4c and d were published erroneously. The revised Fig. 4 is given in this erratum. ...

    journal_title：Breast cancer research and treatment

    pub_type： 已发布勘误

    doi：10.1007/s10549-016-3752-9

    authors： Wander SA,Zhao D,Besser AH,Hong F,Wei J,Ince TA,Milikowski C,Bishopric NH,Minn AJ,Creighton CJ,Slingerland JM

    更新日期：2016-04-01 00:00:00

  • Pre-morbid body-mass-index in breast cancer: reversed effect on survival in hormone receptor negative patients.

    abstract：:The present study consists of 1,238 women with unilateral breast cancer treated with modified radical mastectomy living in the geographic area of Haukeland Hospital. Their weight and height had been measured years before presentation of the disease. Age-adjusted Quetelet's index (weight/height2) showed that obese wome...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01807157

    authors： Maehle BO,Tretli S

    更新日期：1996-01-01 00:00:00

  • Generation of CD8+ cytotoxic T lymphocytes against breast cancer cells by stimulation with mammaglobin-A-pulsed dendritic cells.

    abstract：:Mammaglobin-A is exclusively expressed by breast cancer cells. Thus, mammaglobin-A-specific T cell immune responses may be useful for the design of new breast cancer-specific immunotherapies. We show herein that CD8+ T cells generated against recombinant mammaglobin-A-pulsed dendritic cells display a marked cytotoxic ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1023323509888

    authors： Manna PP,Jaramillo A,Majumder K,Campbell LG,Fleming TP,Dietz JR,Dipersio JF,Mohanakumar T

    更新日期：2003-05-01 00:00:00

  • The synergistic effect between adult weight changes and CYP24A1 polymorphisms is associated with pre- and postmenopausal breast cancer risk.

    abstract：PURPOSE:Vitamin D (VD) metabolism regulates adipose tissue, lipogenesis inflammation, and tumor growth. CYP24A1 is the key enzyme for metabolic inactivation of active VD (1,25(OH)2D3). We examined whether common germline single nucleotide polymorphisms (SNPs) in the CYP24A1 gene could affect the association between adu...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05484-6

    authors： Cao S,Wei F,Zhou J,Zhu Z,Li W,Wu M

    更新日期：2020-01-01 00:00:00

  • Aromatase and its inhibitors in breast cancer treatment--overview and perspective.

    abstract：:Estrogen has an important role in stimulating the growth of breast carcinomas. Inhibition of estrogen production is therefore a logical treatment strategy. A number of selective inhibitors have been developed against aromatase, a cytochrome P-450 enzyme which catalyzes the rate limiting step in the biosynthesis of est...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00682736

    authors： Brodie AM,Santen RJ

    更新日期：1994-01-01 00:00:00

  • Breast cancer risk is not associated with polymorphic forms of xeroderma pigmentosum genes in a cohort of women from Washington County, Maryland.

    abstract：BACKGROUND:The genes mutated in the cancer-prone syndrome, xeroderma pigmentosum (XP genes), have been well studied both biochemically and mechanistically. These genes are important components of the DNA nucleotide excision repair (NER) pathway, which protects against environmentally-induced cancers. XP genes are also ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9263-3

    authors： Jorgensen TJ,Visvanathan K,Ruczinski I,Thuita L,Hoffman S,Helzlsouer KJ

    更新日期：2007-01-01 00:00:00

  • Recurrence outcomes after omission of postoperative radiotherapy following breast-conserving surgery for ductal carcinoma in situ of the breast: a multicenter, retrospective study in Korea (KROG 16-02).

    abstract：PURPOSE:To evaluate the loco-regional recurrence (LRR) rate after breast-conserving surgery without postoperative radiotherapy (RT) for ductal carcinoma in situ (DCIS) of the breast. METHODS:Between 2000 and 2010, 311 DCIS patients from 9 institutions were analyzed retrospectively. The median age was 47 (range, 20-82)...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-017-4111-1

    authors： Kim K,Jung SY,Shin KH,Kim JH,Han W,Lee HB,Huh SJ,Choi DH,Park W,Ahn SD,Kim SS,Kim JH,Suh CO,Kim YB,Kim IA,Kim S,Kim YJ

    更新日期：2017-02-01 00:00:00

  • Is microductectomy still necessary to diagnose breast cancer: a 10-year study on the effectiveness of duct excision and galactography.

    abstract：PURPOSE:Patients with spontaneous nipple discharge (SND) who have neither clinically palpable masses nor evidence of disease on imaging with mammogram and/or ultrasound are traditionally investigated with galactogram and duct excision. As breast imaging improves, it has raised the question whether galactography and mic...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-05109-4

    authors： Lustig DB,Warburton R,Dingee CK,Kuusk U,Pao JS,McKevitt EC

    更新日期：2019-04-01 00:00:00

  • Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

    abstract：:The mutation pattern of breast cancer molecular subtypes is incompletely understood. The purpose of this study was to identify mutations in genes that may be targeted with currently available investigational drugs in the three major breast cancer subtypes (ER+/HER2-, HER2+, and Triple Negative). We extracted DNA from ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2035-3

    authors： Santarpia L,Qi Y,Stemke-Hale K,Wang B,Young EJ,Booser DJ,Holmes FA,O'Shaughnessy J,Hellerstedt B,Pippen J,Vidaurre T,Gomez H,Valero V,Hortobagyi GN,Symmans WF,Bottai G,Di Leo A,Gonzalez-Angulo AM,Pusztai L

    更新日期：2012-07-01 00:00:00

  • Predictive value of lymphoscintigraphy in patients with breast cancer-related lymphedema undergoing complex decongestive therapy.

    abstract：PURPOSE:We evaluated the prognostic value of lymphoscintigraphy after complex decongestive therapy (CDT) in breast cancer-related secondary lymphedema. METHODS:Prior to CDT, 80 patients with breast cancer-related lymphedema underwent a 99mTc tin-colloid lymphoscintigram. We investigated the uptake patterns of axillary...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-5041-2

    authors： Kim YH,Hwang JH,Bae JH,Choi JY

    更新日期：2019-02-01 00:00:00